Sichuan Kelun Biotech (6990)

Currency in HKD
433.00
+28.80(+7.13%)
Closed·
6990 Scorecard
Full Analysis
Significant return over the last week
Trading near 52-week High
Fair Value
Day's Range
405.80435.40
52 wk Range
148.00435.40
Key Statistics
Bid/Ask
433.00 / 433.20
Prev. Close
433
Open
405.8
Day's Range
405.8-435.4
52 wk Range
148-435.4
Volume
1.3M
Average Volume (3m)
834.6K
1-Year Change
161.45%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6990 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
330.26
Downside
-23.73%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Sichuan Kelun Biotech News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Sichuan Kelun Biotech Company Profile

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Compare 6990 to Peers and Sector

Metrics to compare
6990
Peers
Sector
Relationship
P/E Ratio
−316.6x−32.3x−0.5x
PEG Ratio
−5.890.290.00
Price/Book
25.5x6.7x2.6x
Price / LTM Sales
43.7x19.7x3.3x
Upside (Analyst Target)
−24.0%−8.3%43.5%
Fair Value Upside
Unlock−11.2%6.3%Unlock

Analyst Ratings

18 Buy
1 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 330.26
(-23.73% Downside)

Earnings

Latest Release
Apr 17, 2025
EPS / Forecast
-2.59 / -3.27
Revenue / Forecast
550.25M / --
EPS Revisions
Last 90 days

6990 Income Statement

FAQ

What Stock Exchange Does Sichuan Kelun Biotech Trade On?

Sichuan Kelun Biotech is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Sichuan Kelun Biotech?

The stock symbol for Sichuan Kelun Biotech is "6990."

What Is the Sichuan Kelun Biotech Market Cap?

As of today, Sichuan Kelun Biotech market cap is 98.96B.

What Is Sichuan Kelun Biotech's Earnings Per Share (TTM)?

The Sichuan Kelun Biotech EPS (TTM) is -1.20.

From a Technical Analysis Perspective, Is 6990 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sichuan Kelun Biotech Stock Split?

Sichuan Kelun Biotech has split 0 times.

How Many Employees Does Sichuan Kelun Biotech Have?

Sichuan Kelun Biotech has 1837 employees.

What is the current trading status of Sichuan Kelun Biotech (6990)?

As of 05 Aug 2025, Sichuan Kelun Biotech (6990) is trading at a price of 433.00, with a previous close of 433.00. The stock has fluctuated within a day range of 405.80 to 435.40, while its 52-week range spans from 148.00 to 435.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.